INOVIO to Participate in Upcoming Scientific Conference

Rhea-AI Summary

INOVIO (NASDAQ: INO) will present at the World Federation of Hemophilia World Congress in Kuala Lumpur on April 22, 2026. The company will deliver a talk on DNA-Encoded Protein (DPROT) production of functional FVIII and a poster on non-viral DNA medicine FVIII expression in Hemophilia A mice.

Presentations are scheduled at 9:45 AM MYT (talk) and 10:45 AM MYT (poster). According to the company, abstracts will be posted on INOVIO's website after the presentations.

News Market Reaction – INO

% 13.1x vol

40 alerts

% News Effect

-25.5% Trough in 5 hr 33 min

$120.22M Market Cap

13.1x Rel. Volume

On the day this news was published, INO declined NaN%, reflecting a moderate negative market reaction. Argus tracked a trough of -25.5% from its starting point during tracking. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 13.1x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

PLYMOUTH MEETING, Pa., April 1, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following scientific conference:

World Federation of Hemophilia World Congress (Kuala Lumpur)

• Presentation: Next Gen Protein Replacement Therapeutics: DNA-Encoded Protein (DPROT) Technology Demonstrates in vivo Production of Functional FVIII in Mouse Model
  Date: Wednesday, April 22
  Time: 9:45 AM MYT

• Poster Presentation: FVIII Expression Via Non-viral Vector DNA Medicine Platform Results in Efficacious Levels of FVIII Protein and Correction of the Bleeding Phenotype in Hemophilia A Mice
  Date: Wednesday, April 22
  Time: 10:45 AM MYT

Available abstracts will be shared on INOVIO's website following presentations.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo, ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-participate-in-upcoming-scientific-conference-302731455.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

When will INOVIO (INO) present at the World Federation of Hemophilia World Congress in 2026?

INOVIO will present on April 22, 2026 with two sessions scheduled that day. According to the company, a talk is at 9:45 AM MYT and a poster follows at 10:45 AM MYT in Kuala Lumpur.

What topics will INOVIO (INO) cover at the April 22, 2026 conference presentations?

INOVIO will discuss DPROT DNA-encoded protein therapeutics and non-viral DNA medicine FVIII expression. According to the company, sessions report in vivo production of functional FVIII and correction of bleeding in Hemophilia A mice.

Where can investors find INOVIO (INO) abstracts from the April 22, 2026 presentations?

Abstracts will be posted on INOVIO's website after the presentations. According to the company, available abstracts will be shared on the company's site following the April 22, 2026 sessions at the World Federation of Hemophilia Congress.

What time are INOVIO's (INO) two presentations on April 22, 2026 at WFH World Congress?

The scheduled times are 9:45 AM MYT for the DPROT talk and 10:45 AM MYT for the poster. According to the company, both sessions occur on April 22, 2026 in Kuala Lumpur.

How does INOVIO (INO) describe the Hemophilia A preclinical results presented on April 22, 2026?

INOVIO reports that non-viral DNA medicine produced efficacious FVIII levels and corrected bleeding in Hemophilia A mice. According to the company, the poster shows FVIII expression via a non-viral vector DNA platform achieved therapeutic effects in mice.